Molecular diagnostics company Biodesix has acquired Integrated Diagnostics (Indi) and its complementary oncology product, the XL2 test, intended to improve the diagnosis of lung cancer.
The non-invasive test is a pulmonary nodule classifier and requires a simple blood draw. It measures proteins to detect lung nodules with a high possibility of being benign and helps rule out cancer for patients having suspicious nodules.
XL2 is expected to offer an alternative for existing tissue sample extraction technique, which is performed to identify if a nodule is benign or malignant but is expensive and invasive to patients.
Biodesix CEO David Brunel said: “The team at Indi has developed and substantially validated an important test that helps physicians better manage patients who present with a suspicious nodule in their lung.
“Adding XL2 to our portfolio demonstrates our commitment to helping physicians and patients battle lung disease across a continuum of clinical presentations.”
The XL2 test is expected to complement Biodesix’s existing commercial blood-based lung cancer tests designed to allow more informed treatment decisions.
Biodesix VeriStrat proteomic test is developed to offer prognostic information without influence from treatment choice, including immunotherapy.
Its GeneStrat genomic test is formulated to measure actionable mutations associated with non-small cell lung cancer to additionally inform therapeutic decisions and monitoring.
Integrated Diagnostics CEO Al Luderer said: “Indi and Biodesix share important values and technologic synergies that make this an ideal combination, including a singular focus on providing high-value, blood-based diagnostic products for lung disease and the expert application of advanced mass spectrometry and informatics.
“Additionally, we are impressed by Biodesix’s rapidly expanding commercial presence and extensive lung disease product pipeline.”
Financial terms of the acquisition have not been divulged.